A phase 2 clinical trial has revealed promising clinical efficacy for savolitinib in patients with MET-amplified gastric and gastroesophageal junction adenocarcinoma, addressing a significant treatment gap in precision oncology. MET amplification, though present in only 2-4% of gastric cancers according to National Cancer Institute data, represents a molecularly defined subgroup that has lacked targeted therapeutic options.
Savolitinib, a selective MET tyrosine kinase inhibitor, specifically targets this molecular pathway. The trial, presented at the 2026 ASCO Annual Meeting and published in Nature Medicine, employed a structured design incorporating both exploratory and pivotal phases. This approach enabled researchers to optimize therapeutic strategies for this genetically distinct patient population.
These results highlight the continued importance of biomarker-driven drug development in improving outcomes for gastric cancer patients with targetable molecular alterations.
Was this article helpful?
